Lower Hospitalization and Total Healthcare Costs Among Patients with Heart Failure When Treated with Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker: A Retrospective Study of Managed Care Claims

Heart & Lung ◽  
2020 ◽  
Vol 49 (2) ◽  
pp. 211
Author(s):  
Nancy Albert ◽  
Erin Buysman ◽  
Chunlan Chang ◽  
Jason Swindle
Sign in / Sign up

Export Citation Format

Share Document